Shares of Global Blood Therapeutics (GBT +6.7%) have been halted with news pending.
Bloomberg reports the company landed a key approval from the FDA for Oxbryta (voxelotor) as a treatment for sickle cell disease, although there is no official word yet from the company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.